| ROVI Stock | | | EUR 63.05 0.05 0.08% |
CEO
Mr. Juan LopezBelmonte Encina serves as Chief Executive Officer, Executive Director at Laboratorios Farmaceuticos ROVI, S.A. since 2015. Prior to this, he was CoChief Executive Officer, General Director and Executive Director of the Company. He was on the Company Board on July 27, 2007. He also acts as Secretary of the Nominating and Remuneration Committee of the Company. He joined the Company in 1994. In the past, he worked at Nielzen Group, Tyco Group and Boots Pharmaceuticals. He was Director of Bemipharma Manufacturing SL, Gineladius SL, Rovi Contract Manufacturing SL and Inversiones Clidia SL, as well as Chief Executive Officer of Rovi Imaging SL. In addition, he is representative of the Company on the Boards of Alentia Biotech SL, Bemipharma Manufacturing SL, Frosst Iberica SA, Gineladius SL, Pan Quimica Farmaceutica SA and Rovi Contract Manufacturing SL. He obtained a degree in Business and Economics, with a specialization in Audit, from Universidad CEU San Pablo in 1993. since 2015.
| Tenure | 9 years |
| Phone | 34 91 021 30 00 |
| Web | https://www.rovi.es |
Laboratorios Farmaceuticos Management Efficiency
The company has return on total asset
(ROA) of
0.1844 % which means that it generated a profit of $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.3919 %, meaning that it generated $0.3919 on every $100 dollars invested by stockholders. Laboratorios Farmaceuticos' management efficiency ratios could be used to measure how well Laboratorios Farmaceuticos manages its routine affairs as well as how well it operates its assets and liabilities.
Laboratorios Farmaceuticos ROVI has accumulated 52.52
M in total debt with debt to equity ratio
(D/E) of 0.18, which may suggest the company is not taking enough advantage from borrowing. Laboratorios Farmaceuticos has a current ratio of 2.57, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Laboratorios Farmaceuticos until it has trouble settling it off, either with new capital or with free cash flow. So, Laboratorios Farmaceuticos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Laboratorios Farmaceuticos sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Laboratorios to invest in growth at high rates of return. When we think about Laboratorios Farmaceuticos' use of debt, we should always consider it together with cash and equity.
Similar Executives
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. Laboratorios Farmaceticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. LABORATORIOS FARMACEUTICOS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 1499 people. Laboratorios Farmaceuticos ROVI (ROVI) is traded on Madrid Exchange in Spain and employs 1,751 people.
Management Performance
Laboratorios Farmaceuticos Leadership Team
Elected by the shareholders, the Laboratorios Farmaceuticos' board of directors comprises two types of representatives: Laboratorios Farmaceuticos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratorios. The board's role is to monitor Laboratorios Farmaceuticos' management team and ensure that shareholders' interests are well served. Laboratorios Farmaceuticos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratorios Farmaceuticos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Beatriz Alcalde, Sales Manager Line B | |
| Ignacio Toledano, Deputy Sec | |
| Gabriel Fernandez, Non-member Secretary | |
| Fernando Morales, Commercial Director | |
| Miguel Freese, Independent Director | |
| Enrique Leal, Vice Chairman of the Board, Independent Director | |
| Rosario Prez, Marketing Mang | |
| Ivan Encina, First Vice Chairman of the Board, Executive Director of Corporate Development | |
| Jose MorenoBarreda, Independent Director | |
| Miguel Sanchez, Industrial Director | |
| Francisco Garca, HR Mang | |
| Miguel Roman, Director of International Affairs and Development | |
| Pedro Trillo, Director of Hospital Network | |
| Marcos Pinto, Lead Independent Director | |
| Fernando Garijo, Sales Effectiveness Manager | |
| Mercedes Sanchez, Manager - Legal Department | |
| Francisco Garcia, Director of Human Resources | |
| Juan Lopez, Co-CEO, Chairman of the Board, Executive Director | |
| Javier Encina, Second Vice Chairman of the Board, Chief Financial Officer, Executive Director | |
| Fatima Garcia, Independent Director | |
| Pablo Jorge, Chief Economic and Administrative Officer | |
| M Perez, Marketing Manager | |
| Juan Encina, Co-CEO, General Director, Executive Director | |
| Ibon Aduriz, Director of Preclinical Research | |
| Mercedes Snchez, Legal Mang | |
Laboratorios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratorios Farmaceuticos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Laboratorios Stock
Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.